Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.37 |
| ▸ | DRD3 | P35462 | 11/20 | 0.37 |
| ▸ | DRD4 | P21917 | 4/20 | 0.37 |
| ▸ | DRD1 | P21728 | 3/20 | 0.37 |
| ▸ | DRD5 | P21918 | 3/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | CDK7 | P50613 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556212 | 0.89 | MMP1 (0.37) | — | |
| SCHEMBL1804229 | 0.80 | CA12 (0.36) | — | |
| SCHEMBL556469 | 0.78 | ESR1 (0.37) | DRD1 | |
| SCHEMBL2121244 | 0.77 | ESR1 (0.40) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL2121245 | 0.73 | DRD2 (0.38) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL7974143 | 0.72 | ESR1 (0.51) | DRD2DRD3 | |
| SCHEMBL19859319 | 0.71 | DRD2 (0.44) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL11898659 | 0.71 | REN (0.41) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL5156097 | 0.70 | NR1H2 (0.41) | — | |
| SCHEMBL3843083 | 0.69 | ESR2 (0.57) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| EP-2413941-A1 | RENIN INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114978-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | DRD2 2069/4885DRD3 1417/4885DRD4 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.